According to a recent LinkedIn post from Resilience Care, the company reports early 2026 momentum built around collaborative oncology care across Europe. The post highlights that its remote monitoring solution is now used in 160 healthcare institutions, and that over 35,000 patients have received remote follow-up, with 86% reportedly recommending the service.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also notes that Institut Curie has become the second comprehensive cancer center in the Île-de-France region to join Resilience Care’s partner network, signaling deeper penetration into leading French oncology institutions. This type of reference client may support future commercial traction and strengthen the firm’s positioning with other high-profile centers.
In addition, the company’s LinkedIn update points to two new collaborations with Ipsen and Association ARTIC focused on real-world research in uro-oncology. These partnerships suggest potential access to valuable clinical data and may enhance the evidence base around patient pathways and routine care, factors that can be important for reimbursement discussions and long-term adoption.
For investors, the metrics shared in the post, along with ties to prominent oncology players, may indicate increasing scale and validation of Resilience Care’s model within digital and remote cancer care. Continued expansion of institutional clients and data-driven partnerships could improve the company’s competitive position in the European oncology technology market and support future revenue growth prospects.